Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-06-21
2000-05-30
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
060691549
ABSTRACT:
Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride.
REFERENCES:
patent: 4962115 (1990-10-01), Van Daele
patent: 5057525 (1991-10-01), Van Daele
patent: 5114714 (1992-05-01), Young et al.
patent: 5114715 (1992-05-01), Young et al.
patent: 5137896 (1992-08-01), Van Daele
Porsius, A.J., et al., "Farmacotoets 6A," Farmacotherapie, 129:9:214-217 (1994).
Schiavi, G.B., et al., "Identification of Serotonin 5-HT.sub.4 Recognition Sites in the Porcine Caudate Nucleus by Radioligand Binding," Neuropharmacology, 33:543-549 (1994).
Krejs, G.J., "Serotonine intestinale, une cible therapeutique," Med. Chir. Dig., 22:7:415-416 (1993).
Zuccato, E., et al., "The Effects of S(-) and R(+) Sulpiride, Metoclopramide, Cisapride and Domperidone on the Small Intestine Suggest DA.sub.2 -Receptors are Involved in the Control of Small Intestinal Transit Time in Rats," Pharmacological Research, 26:2:179-185 (1992).
Gladziwa, U., et al., "Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis," Clinical Pharmacology, 50:6:673-681 (1991).
Gullikson, G.W., et al., "Relationship of Serotonin-3 Receptor Antagonist Activity to Gastric Emptying and Motor-Stimulating Actions of Prokinetic Drugs in Dogs," Journal of Pharmacology and Experimental Therapeutics, 258(1):103-110 (1991).
Frazer, A., et al., "Subtypes of Receptors for Serotonin," Annual Rev. of Pharmacology and Toxicology, 30:307-348 (1990).
Schapira, M., et al., "The Current Status of Gastric Prokinetic Drugs," Acta Gastroenterolog. Belg. LIII:446-457 (1990).
Clarke, D.E., et al., "The 5-HT.sub.3 Receptor: Naughty, but Nice," Trends in Pharmacological Sciences, 10:385-386 (1989).
Craig & Clark, "5-Hydroxytryptamine and Cholinergic Mechanisms in Guinea-pig lleum," Brit. J. Pharmacol., 96:247 (1989).
Dumuis, A., et al., "The Gastrointestinal Prokinetic Benzamide Derivatives are Agontist at the Non-Classic 5-HT Receptor (5-HT.sub.4) Positively Coupled to Adenylate Cylase in Neurons," N.S. Arch. Pharmacol., 340:403-410 (1989).
Jamali, F., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls," Journal of Pharmaceutical Sciences, 78(9):695-715 (1989).
Nemeth et al., Chemical Abstracts, vol. 111, No. 19, Abs. No. 167161a (1989).
Nemeth, P.R. and Gullikson, G.W., "Gastrointestinal Motility Stimulating Drugs and 5-HT Receptors on Myenteric Neurons," European Journal of Pharmacology, 166:387-391 (1989).
Scrip's New Product Review No. 32 Cisapride, PJB Publications Ltd. (Apr. 1989).
Barnes, N.M., et al, "Identification of 5-HT.sub.3 Recognition Sites in the Ferret Area Postrema," J. Pharm. Pharmacol., 40:586-588 (1988).
Decktor, D.L., et al., "Effect of Metoclopramide, Bethanechol and the Cholecystokinin Receptor Antagonist, L-364, 718, on Gastric Emptying in the Rat," Eur. J. Pharmacol., 147:313-316 (1988).
Lauwers, W., et al., "Identification of a Biliary Metabolite of Cisapride," Biomedical and Environmental Mass Spectrometry, 15:323-328 (1988).
Meuldermans, W., et al., "Excretion and Biotransformation of Cisapride in Dogs and Humans After Oral Administration," Drug Metabolism and Disposition, 16:3:403-419 (1988).
Meuldermans, W., et al., "Excretion and Biotransformation of Cisapride in Rats After Oral Administration," Drug Metabolism and Disposition, 16:3:403-419 (1988).
Van Peer, A., et al., "Clinical Pharmacokinetics of Cisapride," Progress in the Treatment of Gastrointestinal Motility Disorders: The Role of Cisapride, Proceedings of a Symposium in Frankfurt Excerpta Medica, pp. 23-29 (1988).
Barone et al., "Bioavailability of Three Oral Dosage Forms of Cisapride, a Gastrointestinal Stimulant Agent," Clinical Pharmacy, 6:640-645 (1987).
Costall, B., et al., "Emesis Induced by Cisplatin in the Ferret as a Model for the Detection of Anti-Emetic Drugs," Neuropharmacology, 26:1321-1326 (1987).
Stacher et al., "Effects of Oral Cisapride on Interdigestive Jejunal Motor Activity Psychomotor Function, and Side-Effect Profile in Healthy Man," Digestive Disease and Sciences, 32(11):1223-1230 (1987).
Van Daele, G.H.P., et al., "Synthesis of Cisapride, a Gastrointestinal Stimulant Derived From Cis-4-Amino-3-Methoxypiperidine," Drug Development Research, 8:225-232 (1986).
Fernandez & Massingham, "Peripheral Receptor Populations Involved in the Regulation of Gastrointestinal Motility and the Pharmacological Actions of Meoclopramide-like Drugs," Life Sci. 36:1-14 (1985).
Schuurkes, J.A.J., et al., "Motor-Stimulating Properties of Cisapride on Isolated Gastrointestinal Preparations of the Guinea Pig," J. Pharmacol. Exp. Ther., 234:775-783 (1985).
Williams & Burks, "Cisapride Increases Gastric Emptying Without Affecting Small or Large Bowel Transit," Proc. West. Pharmacol. Soc., 28:47-50 (1985).
Milo, R., "Non-Cholinergic, Non-antidopaminergic Treatment of Chronic Digestive Symptoms Suggestive Of A Motility Disorder: A Two-Step Pilot Evaluation of Cisapride," Curr. Therapeutic Research, 36:5:1053-1062 (1984).
Reyntjens, A., et al., "Clinical Pharmacological Evidence For Cisapride's Lack of Antidopaminergic or Direct Cholinergic Properties," Current Therapeutic Research, 36:5:1045-1052 (1984).
Lavrijsen, K., et al., "The Role of CYP3A4 in the In-Vitro Metabolism of Cisapride in Human Liver Microsomes and In-Vitro and In-Vivo Interactions of Cisapride with Co-Administered Drugs," Dept. of Pharmacokinetics and Drug Metabolism, Janssen Research Foundation (1995).
Gray Nancy M.
Young James W.
Jarvis William R. A.
Sepracor Inc.
LandOfFree
Methods for treating gastro-esophageal reflux disease using opti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating gastro-esophageal reflux disease using opti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating gastro-esophageal reflux disease using opti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1910634